Drug Access Listing

Tablet

Not specified

A BC Cancer Compassionate Access Program request must be approved prior to treatment.¹
Restricted funding*²  

Eligibility (Abiraterone + Prednisone)¹:

• Patients with mCRPC who are chemotherapy-naïve OR have received prior chemotherapy containing docetaxel
  • ECOG PS 0-2
  • Life expectancy > 3 months
• Patients can receive abiraterone (UGUPENZ) OR enzalutamide (UGUPABI, but not sequential use of these agents  

Exclusions¹:

• Active or symptomatic viral hepatitis or chronic liver disease
• History of adrenal dysfunction
• Clinically significant heart disease (LVEF < 50% at baseline)
• Previously received abiraterone, enzalutamide or apalutamide for mCSPC
• Previously received apalutamide, enzalutamide or darolutamide in nmCRPC  

Caution¹:

• Bilirubin > 1.5 x ULN, ALT > 2.5 x ULN
• Uncontrolled hypertension  

*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

1. BC Cancer Protocol UGUPABI [2-22] 
2. BC Cancer Benefit Drug List [3-22]

Janssen (Janssen BioAdvance Patient Assistance Program): Access Here
JAMP (JAMP Care): Access Here
Sentrex Health Solutions: Access Here
Pharma-science: Access Here
Apotex: Access Here
ApoAssist: Access Here

Tablet

Not specified

A BC Cancer Compassionate Access Program request must be approved prior to treatment.¹ 
Restricted funding^*2  

Eligibility (Abiraterone + Prednisone)¹:

• Patients with mCSPC who are either chemotherapy-naïve OR received prior chemotherapy containing docetaxel
  • No prior ADT or ADT for < 6 months for mCSPC
• Should have ECOG PS 0-2
• Should have serum potassium > 3.5 mmol/L

Note: Patients treated with abiraterone for mCSPC and develop mCRPC are eligible to receive enzalutamide (but not abiraterone)  
Caution¹: Uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic > 95 mmHg)  

*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

1. BC Cancer Protocol UGUMCSPABI [2-22]
2. BC Cancer Benefit Drug List [3-22]

Janssen (Janssen BioAdvance Patient Assistance Program): Access Here   
JAMP (JAMP Care): Access Here 
Sentrex Health Solutions: Access Here 
Pharma-science: Access Here 
Apotex: Access Here 
ApoAssist: Access Here

10 mg, 70 mg, 70mg/ 5600 IU VitD3 Tablet

Multiple¹

Limited coverage drug requiring Special Authority Request Form²

Eligibility¹:

• Clinical or radiographically documented fracture due to osteoporosis, OR
• Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of ≥ 7.5 mg of prednisone per day and for ≥ 90 consecutive days

1. BC Pharmacare Formulary [3-22] 
2. Limited Coverage Drug Program [3-22]
   https://www2.gov.bc.ca/assets/gov/health/forms/5328fil.pdf

Apotex: Access Here

Tablet, PO, 60mg, 240mg

02478374

A BC Cancer Compassionate Access Program request must be approved prior to treatment.1

Restricted funding*2

Eligibility1:

• Patients with nmCRPC who meet the following criteria:

• Chemotherapy naïve
• ECOG PS 0-2
• PSADT ≤ 10 months
• No radiologic evidence of metastates (negative bone scan, negative CT of pelvis, abdomen, chest)

• Patients with nmCRPC are eligible to receive one of apalutamide (UGUPAPA), darolutamide (UGUNMPDAR), or enzalutamide (UGUNMPENZ, UGUPENZ), but not their sequential use
• Patients who have progressed on apalutamide in nmCRPC (UGUPAPA):

• Are eligible to receive docetaxel (GUPDOC) and/or cabazitaxel in mCRPC
• Are NOT eligible to receive enzalutamide (UGUPENZ) or abiraterone (UGUPABI) in mCRPC

Exclusions1:

• Patients with mCRPC
• Prior enzalutamide or darolutamide in nmCRPC
• Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic > 95 mmHg)

*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

**60 mg tablet funded, 240 mg tablet pending provincial funding decision.

1. BC Cancer Protocol UGUPAPA [8-21] 
2. BC Cancer Benefit Drug List [3-22]

Janssen BioAdvance Patient Assistance Program: Access Here

Tablet, PO, 60mg, 240mg

02478374

A BC Cancer Compassionate Access Program request must be approved prior to treatment. 1  

Restricted funding*2

Eligibility1:
Patients with mCSPC who meet the following criteria:

• Chemotherapy naïve OR received prior chemotherapy containing docetaxel
• No prior ADT or ADT for < 6 months for mCSPC immediately prior to starting current protocol
• Should have ECOG PS 0-2
• Should have serum potassium > 3.5 mmol/L

Exclusions1:
Patients treated with apalutamide for mCSPC and develop mCRPC are NOT eligible to receive abiraterone or enzalutamide 

*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

**60 mg tablet funded, 240 mg tablet pending provincial funding decision.
 

1. BC Cancer Protocol UGUMCSPAPA [12-21] 
2. BC Cancer Benefit Drug List [3-22]

Janssen BioAdvance Patient Assistance Program: Access Here

Tablet

Not specified

A BC Cancer Compassionate Access Program request must be approved prior to treatment.¹

Restricted funding*²

Eligibility¹:

• Patients with nmCRPC who meeting the following criteria:

• No radiological evidence of metastases (negative bone scan, negative CT of pelvis abdomen, chest) within the last 6 months (exception: pelvic lymph nodes < 2 cm in short axis below the aortic bifurcation)
• No prior chemotherapy for nmCRPC
• PSADT ≤ 10 months
• Should have ECOG PS 0-2

• Patients with nmCRPC are eligible to receive apalutamide (UGUPAPA), darolutamide (UGUNMPDAR) or enzalutamide (UGUNMPENZ/UGUNPENZ), but not sequentially.
• Patients who have progressed to mCRPC on darolutamide (UGUNMPDAR) are eligible to received docetaxel, cabazitaxel and radium
• Patients who have progressed to mCRPC on darolutamide (UGUNMPDAR) are not eligible to receive enzalutamide or abiraterone

Exclusions¹:

• Patients with mCRPC (exception: pelvic lymph nodes < 2 cm in short axis below the aortic bifurcation)
• Prior treatment for nmCRPC with apalutamide (UGUPAPA) or enzalutamide (UGUNMPENZ)
• Prior chemotherapy for nmCRPC

*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

1. BC Cancer Protocol UGUNMPDAR [8-21]
2. BC Cancer Benefit Drug List [3-22]

Bayer Patient Support Programs: Access Here

Nubeqa Support Services: Access Here

60 mg / Syr

02343541¹

Limited coverage drug requiring Special Authority Request Form²

Eligibility²:

• Men with osteoporosis AND

• Clinical or radiographically-documented fracture due to osteoporosis
• Contraindication to oral bisphosphonates for one of the following reasons:
• immune-mediated hypersensitivity reaction to oral bisphosphonates OR
• abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia

1. BC Pharmacare Formulary [3-22] 
2. Limited Coverage Drug Program [3-22]

ProVital Program: Access Here

120 mg / 1.7 mL Vial

02368153¹

Covered by BC Pharmacare Plan P (Palliative Drug Benefit). Application form must be submitted prior to treatment initiation²

BC Palliative Care Benefit Application

Eligibility²:

• Patients with mCRPC with bone metastases
• Evidence of castration resistance (progressive disease despite testosterone < 1.7 nmol/L)
• As a supportive care medication, denosumab is not covered by BC Cancer Agency but may be reimbursed by private insurance plans

1. BC Pharmacare Formulary
2. BC Cancer Protocol SCDMAB [5-14]

The VICTORY Program: Access Here

Tablet

Not specified

A BC Cancer Compassionate Access Program request must be approved prior to treatment.¹

Restricted funding*²

Eligibility¹:

• Patients with mCRPC who meet the following criteria:

• Chemotherapy-naïve OR received prior chemotherapy containing docetaxel
• Should have ECOG PS 0-2
• Should have life expectancy > 3 months

• Patients treated with abiraterone for mCSPC (UGUMCSPABI) are eligible to receive enzalutamide (UGUPENZ) for mCRPC
• Patients can receive either enzalutamide (UGUPENZ) or abiraterone (UGUPABI) in mCRPC but not sequential use of these agents

Exclusions¹:

• Previously received enzalutamide, apalutamide or darolutamide for nmCRPC
• Previously received enzalutamide or apalutamide for mCSPC

Caution¹:

• Uncontrolled hypertension

*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

1. BC Cancer Protocol UGUPENZ [12-21]  
2. BC Cancer Benefit Drug List [3-22]

Expedite^® Patient Assistance Program: Access Here

Tablet

Not specified

A BC Cancer Compassionate Access Program request must be approved prior to treatment.¹

Restricted funding*²

Eligibility¹:

• Patients with nmCRPC who meet the following criteria:

• Chemotherapy-naïve
• No radiologic evidence of metastases (negative bone scan, negative CT of pelvis, abdomen, chest)
• ECOG PS 0-2
• PSADT ≤ 10 months

• Patients with nmCRPC are eligible to receive one of apalutamide (UGUPAPA), darolutamide (UGUNMPDAR), or enzalutamide (UGUNMPENZ, UGUPENZ), but not their sequential use
• Patients who have progressed on enzalutamide in nmCRPC (UGUNMPENZ)

• Are eligible to receive docetaxel (GUPDOC) and/or cabazitaxel in metastatic CRPC
• Are NOT eligible to receive enzalutamide (UGUPENZ) or abiraterone (UGUPABI) in metastatic CRPC

Exclusions¹:

• mCRPC
• Prior treatment with apalutamide or darolutamide in nmCRPC
• Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 95 mmHg)

*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

1. BC Cancer Protocol UGUNMPENZ [8-21] 
2. BC Cancer Benefit Drug List [3-22]

Expedite^® Patient Assistance Program: Access Here

Tablet

Not specified

A BC Cancer Compassionate Access Program request must be approved prior to treatment.¹

Restricted funding*²

Eligibility¹:

• Patients with mCSPC who meet the following criteria:

• Chemotherapy-naïve OR received prior chemotherapy containing docetaxel
• No prior ADT or ADT for < 6 months for mCSPC
• Should have ECOG PS 0-2
• Should have serum potassium > 3.5 mmol/L       ​

Exclusions¹:

• Patients treated with enzalutamide for mCSPC and develop mCRPC are not eligible to receive abiraterone (UGUPABI)

*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

1. BC Cancer Protocol UGUMCSPENZ [12-21] 
2. BC Cancer Benefit Drug List [3-22]

Expedite^® Patient Assistance Program: Access Here

Dual-action tablet, PO/ Comprimé à double action, PO: 100mg niraparib/500mg abiraterone acetate

02538563

Pending provincial funding decision

N/A

Janssen BioAdvance Patient Assistance Program: Access Here

100 mg tab | 150 mg tab

100mg: 02475200 | 150mg: 02475219

BC Cancer Protocol Summary for Treatment of Metastatic CastrationResistant Prostate Cancer using Olaparib   

Patients must have:  

• Metastatic castration-resistant prostate cancer (mCRPC),  
• Deleterious germline and/or somatic mutations in homologous recombination repair genes BRCA 1/2 or ATM  
• Progressed on prior ARAT (androgen receptor-axis-targeted) therapy – enzalutamide, abiraterone/predniSONE, apalutamide or darolutamide in the metastatic castration sensitive (mCSPC), nonmetastatic castration-resistant (nmCRPC), or metastatic castration-resistant (mCRPC) prostate cancer setting with or without prior taxane chemotherapy  
• A BC Cancer “Compassionate Access Program” (CAP) approval prior to treatment 

Patients should have:  

• Performance status ECOG 0-2 

BC Cancer Protocol Summary

AstraZeneca Patient Support Program: Access Here

AstraZeneca Patient Assistance Program: Access Here